MNX 160

Drug Profile

MNX 160

Latest Information Update: 31 Aug 1998

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Macronex; Nonindustrial source
  • Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Adult respiratory distress syndrome; Asthma; Cachexia; Diabetes mellitus; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 31 Aug 1998 No-Development-Reported for Multiple sclerosis in USA (PO)
  • 31 Aug 1998 No-Development-Reported for Adult respiratory distress syndrome in USA (PO)
  • 31 Aug 1998 No-Development-Reported for Cachexia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top